Human milk oligosaccharides, brain structure, and cognitive development in infants: A narrative review

Ahmad Suryawan1, Chairunita2, Andy Darma1

  • 1Department of Child Health, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia; Department of Child Health, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

Insights

Human milk oligosaccharides (HMOs) show potential for supporting infant brain development and cognitive function. Evidence suggests specific HMOs like 2-FL and sialylated HMOs may positively impact neurodevelopment, though more research is needed.

Area of Science:

  • Neuroscience
  • Nutritional Science
  • Developmental Biology

Background:

  • Human milk oligosaccharides (HMOs) are key bioactive components in breast milk.
  • HMOs are known to influence gut microbiota and immune system development.
  • Emerging evidence suggests a role for HMOs in early brain maturation and cognitive function.

Purpose of the Study:

  • To review preclinical and clinical evidence on the association between HMOs and brain structure/neurodevelopment.
  • To explore the biological mechanisms linking HMOs to brain outcomes.
  • To identify knowledge gaps and future research directions.

Main Methods:

  • A narrative review of studies identified through PubMed, Scopus, and Web of Science.
  • Inclusion of animal and human studies examining HMOs and cognitive, behavioral, or neurobiological outcomes.
  • Qualitative thematic synthesis of 18 selected studies.

Main Results:

  • Preclinical studies suggest specific HMOs (e.g., 2'-FL, 3'-SL, 6'-SL) may enhance learning, memory, and emotional regulation.
  • Proposed mechanisms include gut-brain signaling, microbiota modulation, and support for synaptogenesis/myelination.
  • Human studies associate higher concentrations of certain HMOs with improved cognitive, language, motor, and executive functions, supported by MRI findings on brain maturation.

Conclusions:

  • Current evidence suggests a potential role for HMOs in early neurodevelopment.
  • Specific HMOs and their combinations may influence brain structure and function.
  • Further large-scale longitudinal studies and RCTs are required to confirm causality and determine optimal HMO interventions.